Oramed Pharmaceuticals (ORMP) Non Operating Income (2022 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Non Operating Income came in at $44.8 million in Q1 2026, up 1853.28% YoY from $2.3 million in Q1 2025, and up 195.53% on a QoQ basis from $15.2 million in Q4 2025.
Oramed Pharmaceuticals (ORMP) Non Operating Income (2022 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 5 years of Non Operating Income data on file, last reported at $44.8 million in Q1 2026.
- Quarterly Non Operating Income rose 1853.28% year-over-year to $44.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136.9 million (up 1477.98% YoY) and the FY2025 annual result came in at $89.5 million, up 4013.12% from the prior year.
- Non Operating Income improved to $44.8 million in Q1 2026, from $15.2 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $61.5 million in Q3 2025 to a low of -$15.4 million in Q3 2024.
- A 5-year average of $10.5 million and a median of $2.5 million in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income sank 3644.83% — and 2026, when it surged 1853.28%.
- Tracing ORMP's Non Operating Income over 5 years: stood at $1.0 million in 2022, then jumped by 1731.08% to $18.4 million in 2023, then slumped by 133.66% to -$6.2 million in 2024, then surged by 345.25% to $15.2 million in 2025, then soared by 195.53% to $44.8 million in 2026.
- The last three Non Operating Income figures came in at $44.8 million (Q1 2026), $15.2 million (Q4 2025), and $61.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | 103.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 103.74 Mn |
| Mar 31, 2026 | 44.85 Mn |
| Dec 31, 2025 | 15.18 Mn |
| Sep 30, 2025 | 61.47 Mn |
| Jun 30, 2025 | 15.37 Mn |
| Mar 31, 2025 | -2.56 Mn |
| Dec 31, 2024 | -6.19 Mn |
| Sep 30, 2024 | -15.42 Mn |
| Jun 30, 2024 | 14.23 Mn |
| Mar 31, 2024 | 5.09 Mn |
| Dec 31, 2023 | 18.38 Mn |
| Sep 30, 2023 | 435,000.00 |
| Jun 30, 2023 | 2.48 Mn |
| Mar 31, 2023 | 1.60 Mn |
| Dec 31, 2022 | 1.00 Mn |
| Sep 30, 2022 | 1.04 Mn |